Vitamin C Shows Promise in Phase II Trial of Pre-Leukemia Blood Disorders
The phase 2 EVITA trial found 1,000 mg of daily oral vitamin C cut adverse events and showed a possible survival signal in 109 patients.
- On Monday, the phase 2 EVITA clinical trial published results in the American Cancer Society journal CANCER showing that patients with pre-leukemia blood disorders taking 1,000 mg of oral vitamin C daily for one year experienced fewer adverse events.
- Researchers launched the 109-person study because patients with CCUS and MDS often face limited treatment options beyond monitoring, investigating whether vitamin C could support TET2 enzymes that suppress cancer cell growth.
- Although the study did not significantly slow the expansion of abnormal blood-cell clones, researchers observed that vitamin C altered levels of inflammatory cytokines, suggesting the supplement may influence the biological environment where pre-cancerous cells evolve.
- An exploratory analysis found participants who received vitamin C were significantly more likely to be alive after approximately three years of follow-up, though investigators cautioned this survival signal requires further confirmation.
- These preliminary findings position vitamin C as a potential tool for cancer interception, though the team cautioned it is too early to change clinical practice without confirmation in a larger phase 3 clinical trial.
11 Articles
11 Articles
A phase II trial administered a supplement to people with precancerous blood disorders and demonstrated a higher probability of staying alive at 3 years
Vitamin C linked to improved outcomes in people with precancerous blood disorders
Vitamin C boosts the activity of cellular proteins called TET enzymes that help control which genes are turned on or off. Because decreased function of TET enzymes is a common driver of certain forms of blood cancer, researchers tested the effects of vitamin C supplements in patients at risk of developing such malignancies.
Copenhagen – An oral vitamin C supplementation could benefit patients with myeloid blood cancer at early stages. In a phase 2 study, inflammatory cytokine patterns were altered and overall survival was prolonged compared to placebo (Cancer 2026; DOI: 10.1002/cncr.70549).
Hematology and Naiarabrocal Hemotherapy In 'Cancer' A Phase II clinical trial suggests that vitamin C supplementation could have beneficial effects in people with early-stage precancerous blood disorders and haematological cancers. The randomised, double-blind, placebo-controlled EVITA study evaluated the one-year daily administration of 1,000 mg of oral vitamin C. The study included 109 patients from Denmark and the United States who had a bloo…
Coverage Details
Bias Distribution
- 75% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
